Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.

Lim, Mir; Lynch, Patrick T; Bai, Xiaochen; Hsiehchen, David

Lim, Mir; Lynch, Patrick T; Bai, Xiaochen; Hsiehchen, David.

Afiliación

Lim M; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Lynch PT; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Bai X; Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX.
Hsiehchen D; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.

JCO Precis Oncol ; 7: e2200340, 2023 01.

Article en En | MEDLINE | ID: mdl-36634295

Asunto(s)

Neoplasias de los Conductos Biliares; Colangiocarcinoma; Humanos; Ligandos; Colangiocarcinoma/tratamiento farmacológico; Colangiocarcinoma/genética; Conductos Biliares Intrahepáticos/patología; Neoplasias de los Conductos Biliares/tratamiento farmacológico; Neoplasias de los Conductos Biliares/genética; Neoplasias de los Conductos Biliares/patología; Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Colangiocarcinoma Límite: Humans Idioma: En Revista: JCO Precis Oncol Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google